The Ankylosing Spondylitis Therapeutics Market is Forecast to Show Moderate Growth until 2019

Wednesday 8 February 2012, Amsterdam

The report is an essential source of information and analysis on the global Ankylosing Spondylitis Therapeutics market. The report identifies the key trends shaping and driving the global Ankylosing Spondylitis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Ankylosing Spondylitis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The Ankylosing Spondylitis Therapeutics Market is Forecast to Show Moderate Growth until 2019

The estimates that the global ankylosing spondylitis therapeutics market had a value of $1,112m in 2011, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5.1% over the next eight years to reach $1,650m by 2019. The market will witness several patent expiries of drugs including NSAIDs such as Celebrex (celecoxib) (2014 in the US and Europe) and biologics such as Enbrel (etanercept) (2012 in the US, and 2015 in Europe), Remicade (infliximab) (2014 in the US and Europe), and Humira (adalimumab) (2016 in the US and 2018 in Europe). In addition to this, the prevalence of ankylosing spondylitis is expected to remain stable over the forecast period. However, pipeline molecules such as AIN457 (secukinumab) and Cimzia (certolizumab pegol) are expected to launch in 2015. GlobalData expects these factors to account for moderate growth within the ankylosing spondylitis therapeutics market to 2019.

During the period 2000-2006, Celebrex, Enbrel, Remicade and Humira were approved for the treatment of ankylosing spondylitis. Increased uptake of these approved drugs resulted in the relatively high market growth witnessed throughout the period 2006-2011.

See figure: Ankylosing Spondylitis Therapeutics Market, Global, Revenue and Forecasts ($m), 2006–2019
 

Ankylosing Spondylitis Market Has Moderate Unmet Need

The ankylosing spondylitis therapeutics market has moderate unmet need. The market is served by drug classes such as:
• Nonsteriodal anti-inflammatory drugs (NSAIDs) including ibuprofen, naproxen, indomethacin, diclofenac, Arcoxia (eterocoxib) and Celebrex
• Disease modifying anti-rheumatic drugs (DMARDs) including sulfasalazine, methotrexate
• Corticosteroids (prednisone)
• Biologics (Enbrel, Humira, Remicade, and Simponi)

These currently marketed drugs have moderate efficacy and safety profiles. The medications used either provide symptomatic relief or halt disease progression. This indicates that the market is in need of drugs that can cure the disease rather than providing symptomatic relief. Therefore, the ankylosing spondylitis therapeutics market is wide open for novel entrants with superior efficacy and safety to fulfill the existing unmet need.

Strong Pipeline Candidates are expected to Intensify Future Competition 

The analysis suggests that the ankylosing spondylitis therapeutics pipeline is strong. It consists of 16 molecules in different phases of development. There are approximately six first-in-class molecules; one molecule in Phase III, four in Phase II and one in preclinical stage of development. AIN457 (secukinumab), currently in Phase III, has the potential to compete with the currently marketed drugs.

This drug has shown a better efficacy and safety profile than the currently marketed drugs. Drugs in the pipeline have shown encouraging response rates in pretreated patients and have great potential in ankylosing spondylitis therapeutics market. These molecules are expected to meet some of the unmet needs of the market. They may also lead to an intensely competitive market. In summary, the global ankylosing spondylitis therapeutics market is becoming a highly competitive landscape.